Results 31 to 40 of about 339,808 (204)

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden [PDF]

European Respiratory Journal, 2016
The effects of pneumococcal conjugated vaccines (PCVs) need to be investigated. In Stockholm County, Sweden, PCV7 was introduced in the childhood immunisation programme in 2007 and changed to PCV13 in 2010.
Ilias Galanis, Ann Lindstrand, Jessica Darenberg, Sarah Browall, Priyanka Nannapaneni, Karin Sjöström, Eva Morfeldt, Pontus Nauclér, Margareta Blennow, Åke Örtqvist, Birgitta Henriques‐Normark   +10 more
openalex   +2 more sources

Impact of COVID-19 Nonpharmaceutical Interventions on Pneumococcal Carriage Prevalence and Density in Vietnam

Microbiology Spectrum, 2023
Nonpharmaceutical interventions (NPIs) implemented to contain SARS-CoV-2 have decreased invasive pneumococcal disease. Previous studies have proposed the decline is due to reduced pneumococcal transmission or suppression of respiratory viruses, but the ...
Monica Larissa Nation, Sam Manna, Hau Phuc Tran, Cattram Duong Nguyen, Le Thi Tuong Vy, Doan Y. Uyen, Tran Linh Phuong, Vo Thi Trang Dai, Belinda Daniela Ortika, Ashleigh Christina Wee-Hee, Jemima Beissbarth, Jason Hinds, Kathryn Bright, Heidi Smith-Vaughan, Thuong Vu Nguyen, Kim Mulholland, Beth Temple, Catherine Satzke   +17 more
doaj   +1 more source

Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease

Pediatrics, 2020
Two PCVs are licensed for prevention of pneumococcal disease. Uncertainty about the effectiveness against AOM and serotype 19A invasive disease in children ≤5 years remains.
Melissa Berman-Rosa, Shauna O’Donnell, Mackenzie Barker, C. Quach   +3 more
semanticscholar   +1 more source

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

Pathogens, 2020
Adult vaccination is high on the agenda in many countries. Two different vaccines are available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide vaccine (PPV23), and a 13-valent conjugated vaccine (PCV13). The objective of
Jacob Dag Berild, B. Winje, D. Vestrheim, H. Slotved, P. Valentiner-Branth, A. Roth, Jann Storsäter   +6 more
semanticscholar   +1 more source

Nasopharyngeal bacterial load as a marker for rapid and easy diagnosis of invasive pneumococcal disease in children from Mozambique.

PLoS ONE, 2017
BackgroundCurrent diagnostic methods for detection of Streptococcus pneumoniae in children with suspected invasive pneumococcal disease have limitations of accuracy, timeliness, and patient convenience.
Pedro Brotons, Quique Bassat, Miguel Lanaspa, Desiree Henares, Amaresh Perez-Arguello, Lola Madrid, Reyes Balcells, Sozinho Acacio, Maria Andres-Franch, Maria Angeles Marcos, Ana Valero-Rello, Carmen Muñoz-Almagro   +11 more
doaj   +1 more source

Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil

Brazilian Journal of Infectious Diseases, 2016
Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two ...
Carolina Regis Leite, Jailton Azevedo, Vivian Santos Galvão, Otávio Moreno-Carvalho, Joice Neves Reis, Cristiana Nascimento-Carvalho   +5 more
doaj   +1 more source

Major Adverse Cardiovascular Events During Invasive Pneumococcal Disease are Serotype Dependent.

Clinical Infectious Diseases, 2020
BACKGROUND Up to 30% of patients admitted to hospitals with invasive pneumococcal disease (IPD), experience major adverse cardiovascular event (MACE) including new/worsening heart failure, new/worsening arrhythmia, and/or myocardial infarction ...
Hector F Africano, Cristian C Serrano-Mayorga, Paula C Ramirez-Valbuena, I. Bustos, A. Bastidas, H. Vargas, Sandra Gómez, Alejandro Rodríguez, C. Orihuela, L. Reyes   +9 more
semanticscholar   +1 more source

Rare but not forgotten: A case of meningitis due to ceftriaxone-resistant Streptococcus pneumoniae

IDCases, 2018
Despite the dramatic decrease in invasive pneumococcal disease since the widespread use of the first pneumococcal vaccine, invasive and resistant disease still occurs.
Naomi Hauser, Miguel E. Cervera-Hernandez, John Lonks, Najam Zaidi   +3 more
doaj   +1 more source

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies

Lancet Global Health, 2020
Summary Background The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype
N. Bar-Zeev, T. Swarthout, D. Everett, M. Alaerts, J. Msefula, C. Brown, Sithembile Bilima, J. Mallewa, Carina King, A. von Gottberg, J. Verani, C. Whitney, C. Mwansambo, S. Gordon, N. Cunliffe, N. French, R. Heyderman   +16 more
semanticscholar   +1 more source

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Emerging Infectious Diseases, 2020
The decline in the proportion of pneumococcal conjugate vaccine (PCV)–covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because ...
Reiko Shimbashi, Motoi Suzuki, B. Chang, Hiroshi Watanabe, Y. Tanabe, K. Kuronuma, Kengo Oshima, Takaya Maruyama, H. Takeda, K. Kasahara, J. Fujita, J. Nishi, T. Kubota, K. Tanaka-Taya, T. Matsui, T. Sunagawa, K. Oishi   +16 more
semanticscholar   +1 more source